AI in Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (Software Solutions, Hardware, Services), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others), By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others), By Region & Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 719.12 Million
CAGR (2026-2031)	9.56%
Fastest Growing Segment	Chemotherapy
Largest Market	North America
Market Size (2031)	USD 1243.69 Million

Market Overview

The Global AI in Oncology Market is projected to grow from USD 719.12 Million in 2025 to USD 1243.69 Million by 2031 at a 9.56% CAGR. Artificial intelligence (AI) in oncology refers to the deployment of advanced algorithms and machine learning techniques to process vast and intricate cancer-related data, aiming to improve detection, diagnosis, treatment, and patient care. The market's growth is primarily driven by the escalating global incidence of cancer, the increasing demand for precision oncology, and continuous advancements in diagnostic technologies and healthcare infrastructure. According to AdvaMed, as of December 2025, over 1,300 AI-enabled medical devices have received FDA authorization, reflecting substantial innovation in this sector.

However, a notable impediment to market expansion remains the complex regulatory landscape and variable reimbursement pathways for AI solutions. These factors can hinder timely clinical adoption and restrict widespread patient access to these evolving technologies across diverse healthcare settings.

Key Market Drivers

Rising global cancer burden
The increasing global cancer incidence and mortality burden significantly propels the AI in oncology market. The sheer scale of new diagnoses and deaths annually creates an urgent demand for more efficient and accurate tools in cancer care. According to a recent analysis referenced in the AACR Cancer Progress Report 2024, there were an estimated 20 million new cancer cases and over 10.3 million deaths from cancer in 2025. This immense burden stresses existing healthcare systems, necessitating innovative solutions that can enhance early detection, personalize treatment strategies, and improve patient outcomes on a global scale. AI technologies offer the potential to sift through vast datasets, identify complex patterns indicative of disease, and assist clinicians in managing the growing patient population, thereby directly addressing this critical public health challenge.

Advancements in AI and investment in oncology
Continuous advancements in artificial intelligence and machine learning technologies further drive the expansion of the AI in oncology market. Breakthroughs in algorithm development and computational power enable AI systems to perform increasingly sophisticated tasks, from predictive analytics to image analysis. For instance, according to ScienceDaily, March 21, 2026, an AI tool named MangroveGS can predict metastasis and colon cancer recurrence with nearly 80% accuracy, surpassing existing methods. These technological leaps facilitate the creation of highly effective diagnostic and therapeutic support tools, leading to improved clinical workflows and more precise interventions. The ongoing innovation attracts substantial investment into the sector; according to IntuitionLabs, in May 2026, oncology-related mergers and acquisitions deals in late 2025 through early 2026 were estimated to total on the order of $12–15 billion. This financial influx supports continued research and development, fostering a cycle of innovation and adoption.

Download Free Sample Report

Key Market Challenges

The complex regulatory landscape and variable reimbursement pathways for AI solutions represent a significant impediment to the growth of the global AI in oncology market. These factors directly hinder the timely clinical adoption of advanced AI algorithms and machine learning techniques designed to improve cancer detection, diagnosis, treatment, and patient care. The uncertainty surrounding approval processes and the lack of standardized guidelines create protracted timelines for market entry, delaying the availability of innovative AI tools to healthcare providers.

Furthermore, the absence of clear and consistent reimbursement policies across diverse healthcare settings restricts widespread patient access to these evolving technologies. According to the Medical Device Manufacturers Association (MDMA), in 2025, over 60% of AI-enabled oncology solutions in the United States were still awaiting dedicated reimbursement codes or navigating provisional payment pathways, significantly impacting their market uptake. This financial ambiguity deters healthcare institutions from investing in and integrating AI oncology solutions, thereby stifling market expansion and limiting the broader application of these advancements in cancer care.

Key Market Trends

The integration of multi-omics and multi-modal data for holistic insights represents a pivotal trend. This involves combining diverse biological datasets, such as genomics, proteomics, and imaging, with clinical information to create a comprehensive understanding of cancer. Such integrated approaches are crucial for advancing precision oncology by providing deeper insights into disease mechanisms and treatment responses. For instance, according to an article published in PMC, November 21, 2025, autonomous AI agents integrating histopathology images with genomic data achieved 91% accuracy in diagnosing microsatellite instability from routine slides, surpassing traditional methods. This capability enables more accurate diagnostics and personalized treatment strategies, enhancing the efficacy of cancer care.

Accelerated AI-powered drug discovery and development pipelines constitute another significant trend reshaping the oncology market. Artificial intelligence streamlines various stages of drug development, from target identification to lead optimization, significantly reducing the time and cost associated with bringing new therapies to market. This efficiency gain is particularly impactful in oncology, where the complexity of cancer biology often extends development timelines. According to Yicai Global, January 26, 2026, in its article "2026: The Dawn of AI-Driven Drug Development," more than 3,000 AI-assisted drugs are currently in development. This substantial pipeline underscores AI's transformative role in generating novel therapeutic candidates and expediting their progression through preclinical and clinical phases.

Segmental Insights

The Chemotherapy segment is experiencing rapid expansion within the Global AI in Oncology Market, driven by its extensive application and the inherent complexities involved in treatment optimization. Artificial intelligence is increasingly vital in personalizing chemotherapy regimens through the analysis of vast datasets, including clinical records, genomic profiles, and clinical trial outcomes. This analytical capability enables oncologists to select effective drug combinations, refine dosing schedules, and determine optimal treatment durations for individual patients. Furthermore, AI-powered prediction algorithms are crucial in anticipating patient tolerance and response to therapies, addressing challenges like medication resistance, and ultimately enhancing treatment plan efficacy.

Regional Insights

North America leads the Global AI in Oncology Market due to its robust healthcare ecosystem and advanced digital infrastructure. The region benefits from supportive regulatory frameworks, including pathways established by bodies such as the Food and Drug Administration (FDA) for AI approvals, alongside favorable reimbursement policies. Furthermore, significant investments in AI research and development by both private and public sectors, coupled with a high demand for precision medicine, accelerate the adoption of AI-powered solutions for cancer diagnosis and treatment. These factors collectively foster a conducive environment for market growth and technological integration in oncology.

Recent Developments

• In May 2026, Flatiron Health introduced Flatiron Telescope, a next-generation AI-powered platform designed to provide oncology insights in minutes for life sciences teams and researchers. This new product aims to streamline the process of identifying suitable patients, assessing study feasibility in real time, and generating critical oncology insights on demand. The platform effectively translates complex patient inclusion and exclusion criteria into actionable cohorts using natural language, empowering non-technical users to progress from data to informed decisions rapidly without requiring coding expertise. This development is set to transform the utilization of real-world data, thereby enhancing decision-making capabilities within the global AI in oncology market.
• In May 2026, AstraZeneca and Roche Diagnostics Asia Pacific entered into a collaboration to enhance the adoption of AI-enabled cancer biomarker testing across nine markets in Asia. This strategic three-year memorandum of understanding aims to implement educational programs to increase the utilization of computational pathology. The initiative seeks to address existing diagnostic challenges and a notable gap in knowledge and adoption of AI-assisted pathology throughout the region. By integrating AI-powered computational pathology into diagnostic workflows, the partnership endeavors to support more precise patient identification for targeted therapies, significantly advancing precision diagnostics within the global AI in oncology market.
• In March 2026, PharmaMar, a global leader in the discovery and development of marine-derived anti-cancer drugs, announced a strategic collaboration with Globant, a digitally native company, aimed at accelerating cancer drug discovery through artificial intelligence. This new alliance introduced a multi-agent AI framework designed to support faster, data-driven decisions within oncology research. The agentic AI system demonstrated substantial efficiency, achieving insights up to 15 times faster with over 90% accuracy. This platform is capable of analyzing extensive scientific, regulatory, and clinical data, enabling scientists to more rapidly select high-potential drug candidates for clinical development, thereby advancing PharmaMar’s research and development efforts in the global AI in oncology market.
• In June 2025, Dxcover, a UK-based company focused on improving early cancer detection, officially launched its United States headquarters in Nashville, Tennessee. This expansion underscored the company's commitment to commercializing its AI-powered multiomic cancer test, PANAROMIC™. The innovative technology utilizes infrared spectroscopy and AI-driven spectral analysis to capture a comprehensive biological signature from small blood samples. This approach is intended to facilitate earlier diagnosis and enhance patient outcomes across various cancer types, including brain, colorectal, lung, and pancreatic cancers. The new facilities are expected to foster partnerships and support local manufacturing, further solidifying Dxcover’s presence in the global AI in oncology diagnostics market.

Key Market Players

• Siemens Healthineers AG
• GE HealthCare Technologies Inc.
• Koninklijke Philips N.V.
• Fujifilm Holdings Corporation
• Tempus AI, Inc.
• PathAI, Inc.
• Flatiron Health, Inc.
• Guardant Health, Inc.
• Paige AI, Inc.
• Microsoft Corporation

By Component	By Cancer Type	By Treatment Type	By Region
Software Solutions Hardware Services	Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Brain Tumor Others	Chemotherapy Radiotherapy Immunotherapy Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global AI in Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• AI in Oncology Market, By Component:

• Software Solutions
• Hardware
• Services

• AI in Oncology Market, By Cancer Type:

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Brain Tumor
• Others

• AI in Oncology Market, By Treatment Type:

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Others

• AI in Oncology Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE